The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Open accessAbstract
Summary Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and tumor cells in breast cancer has been reported, but the relationships between PD-L1 expression by TIL, carcinoma cells, and other immunologic features of the breast tumor microenvironment remain unclear. We therefore evaluated the interrelationships between tumor cell surface and TIL PD-L1 expression, lymphocyte subpopulations, and patterns of immune cell infiltration in cohorts of treatment-naive, primary breast cancers (PBCs) (n = 45) and matched PBC and metastatic breast cancers (MBC) (n = 26). Seventy-eight percent of untreated PBCs contained PD-L1+ TILs, but only 21% had PD-L1+ carcinoma cells. Carcinoma PD-L1 expression localized to the tumor invasive front and was associated with high tumor grade (P = .04). Eighty-nine percent of PD-L1+ carcinomas contained brisk TIL infiltrates, compared to only 24% of PD-L1− carcinomas; this included CD3+ (P = .02), CD4+ (P = .04), CD8+ (P = .002), and FoxP3+ T cells (P = .02). PD-L1+ PBCs were more likely to contain PD-L1+ TIL than PD-L1− PBCs (P = .04). Peripheral lymphoid aggregates were present in 100% of PD-L1+ compared to 41% of PD-L1− PBC (P < .001). No patient with PD-L1+ PBC developed distant recurrence, compared to 15% of patients with PD-L1− PBC. For the matched PBC and MBC cohort, 2 patients (8%) had PD-L1+ tumors, with 1 case concordant and 1 case discordant for carcinoma PD-L1 expression in the PBC and MBC. Our data support PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“A previous study of melanoma and renal cell carcinomas reported heterogeneity of PD-L1 status between different sites of metastases in the same patient [35].”
BackgroundSelf-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Expression and quantification of PD-L1 staining on carcinomas and TILs IHC for PD-L1 (B7-H1) was performed on whole sections of 45 PBCs and on TMAs of 26 matched PBC/MBC using the murine anti-human PD-L1 antibody, clone 5H1 (2 μg/mL) paired with a isotype-matched mouse IgG1 control using established methods [15,17].”
BackgroundMethodPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“The major ligand for PD-1, PD-L1 (B7-H1), can be expressed by tumor cells themselves, as well as by immune cells [14] including infiltrating T cells, B cells, macrophages, and dendritic cells, and the presence of tumoral PD-L1+ TIL correlates with clinical response to PD-1 pathway blockade with anti–PD-1 [15] or anti–…”
BackgroundElkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Self-citationNielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Cited by
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Self-citationThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Self-citationTertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863
Self-citationClinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner, J., Rapsomaniki, M. A., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 790
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Self-citationStanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 631
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30026-9 · Cited by 453
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 440
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
Towards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 363
Implications of the tumor immune microenvironment for staging and therapeutics
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., et al. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.156 · Cited by 358
Self-citationRecent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Immunological differences between primary and metastatic breast cancer
Szekely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., Silber, A., Park, T., Harigopal, M., Pelekanou, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy399 · Cited by 354
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Inflammatory breast cancer biology: the tumour microenvironment is key
Lim, B., Woodward, W. A., Wang, X., Reuben, J. M., & Ueno, N. T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0010-y · Cited by 326
Emens, L. A., Molinero, L., Loi, S., Rugo, H. S., Schneeweiss, A., Diéras, V., Iwata, H., Barrios, C. H., Nechaeva, M., Nguyen-Duc, A., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab004 · Cited by 304
Self-citationPathology of triple negative breast cancer
Borri, F., & Granaglia, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.005 · Cited by 300
Oliva, M., Spreafico, A., Taberna, M., Alemany, L., Coburn, B., Mesia, R., & Siu, L. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy507 · Cited by 260
Immunotherapy for Breast Cancer: What Are We Missing?
Vonderheide, R. H., Domchek, S. M., & Clark, A. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2569 · Cited by 233
Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01188-4 · Cited by 122
“For example, in a digital pathology analysis of tumor tissue samples from 43 patients with breast cancer, the density of CD8 T cells can differ with more than 3 orders of magnitude 38 .”
BackgroundReddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0619 · Cited by 106
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Immunotherapeutic strategies in breast cancer: a clinical update
Zhang, J. Q., & Plitas, G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26287 · Cited by 6
Metadata
- Authors
- Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., Cuka, N., Argani, P., & Emens, L. A.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 47
- Issue
- 1
- Pages
- 52-63
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W1896351481
- Cited by
- 336
- References
- 37
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.